Biosynex SA
PAR:ALBIO
Intrinsic Value
Biosynex SA engages in the development, production, and distribution of Rapid Diagnostics Tests (RDTs) for pathologies. [ Read More ]
The intrinsic value of one ALBIO stock under the Base Case scenario is hidden EUR. Compared to the current market price of 4.06 EUR, Biosynex SA is hidden .
Valuation Backtest
Biosynex SA
Run backtest to discover the historical profit from buying and selling ALBIO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Biosynex SA
Current Assets | 125.8m |
Cash & Short-Term Investments | 45.3m |
Receivables | 30.8m |
Other Current Assets | 49.7m |
Non-Current Assets | 146.4m |
Long-Term Investments | 2.6m |
PP&E | 17.3m |
Intangibles | 126.5m |
Other Non-Current Assets | -1k |
Current Liabilities | 107.6m |
Accounts Payable | 14.4m |
Accrued Liabilities | 11.9m |
Short-Term Debt | 198k |
Other Current Liabilities | 81m |
Non-Current Liabilities | 27.9m |
Long-Term Debt | 16.9m |
Other Non-Current Liabilities | 11m |
Earnings Waterfall
Biosynex SA
Revenue
|
93.1m
EUR
|
Operating Expenses
|
-101.9m
EUR
|
Operating Income
|
-8.9m
EUR
|
Other Expenses
|
-4.9m
EUR
|
Net Income
|
-13.8m
EUR
|
Free Cash Flow Analysis
Biosynex SA
ALBIO Profitability Score
Profitability Due Diligence
Biosynex SA's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
Biosynex SA's profitability score is hidden . The higher the profitability score, the more profitable the company is.
ALBIO Solvency Score
Solvency Due Diligence
Biosynex SA's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
Biosynex SA's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALBIO Price Targets Summary
Biosynex SA
According to Wall Street analysts, the average 1-year price target for ALBIO is 12.85 EUR with a low forecast of 12.73 EUR and a high forecast of 13.23 EUR.
Shareholder Return
ALBIO Price
Biosynex SA
Average Annual Return | 128.15% |
Standard Deviation of Annual Returns | 237.63% |
Max Drawdown | -84% |
Market Capitalization | 40.6m EUR |
Shares Outstanding | 10 760 900 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Biosynex SA engages in the development, production, and distribution of Rapid Diagnostics Tests (RDTs) for pathologies. The company is headquartered in Illkirch-Graffenstaden, Grand Est. The company went IPO on 2011-03-21. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). The company operates through Fumouze Diagnostics and SR2B.
Contact
IPO
Employees
Officers
The intrinsic value of one ALBIO stock under the Base Case scenario is hidden EUR.
Compared to the current market price of 4.06 EUR, Biosynex SA is hidden .